• Addex Therapeutics affiliate Neurosterix closed a $105 million Series B financing today from a syndicate of life science investors.
• Addex did not participate; its equity interest now represents 8.5% of issued capital, valued at $18.6 million.
• Proceeds will mainly fund planned Phase 2 clinical development of NTX-253 for schizophrenia, while also supporting Neurosterix's broader neuropsychiatric pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611111632OMX_____CNEWS_EN_GNW1001303155_en) on November 11, 2026, and is solely responsible for the information contained therein.